Organisation paid for research Program year 2024 Source: CMS Open Payments

Alpesh D Desai Dopa

Neither a doctor nor a teaching hospital

Research payments

$367,062

86 payments

Through program year 2024, Alpesh D Desai Dopa is reported as receiving $367,062 in research payments, across 86 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$12,535	8
2023	Research	$50,630	24
2022	Research	$113,767	27
2021	Research	$190,129	27

Breakdown

Who paid Research payments · program years 2021–2024

AbbVie, Inc. $367,062 86 payments

Studies the money was for Research payments · program years 2021–2024

A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) $109,269 18 payments
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA (Adalimumab) in Adult Patients with Chronic Plaque Psoriasis (PS) $71,554 5 payments
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) $63,671 14 payments
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) $62,449 31 payments
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis $28,145 9 payments
Chronic Plaque Psoriasis (PS) Registry $19,732 7 payments
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) (Measure Up 1) $7,242 1 payment
IMMprint: A Phase 3b Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study Evaluating Safety and Efficacy of Risankizumab Compared to Placebo in Adult Subjects with Moderate to Severe Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement (PPPsO) $5,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.